Simulations Plus Gestion
Gestion contrôle des critères 3/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Shawn O'Connor
Directeur général
US$1.1m
Rémunération totale
| Pourcentage du salaire du PDG | 47.85% |
| Durée du mandat du directeur général | 1.3yrs |
| Propriété du PDG | n/a |
| Durée moyenne d'occupation des postes de direction | 1.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5.2yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • Apr 29
SLP: AI Regulatory Collaborations And Modest Growth Outlook Will Shape Balanced Future
Analysts have maintained their $16.00 price target for Simulations Plus, noting that slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E broadly offset one another in their updated models. What's in the News Announced a funded research collaboration with Lonza Group and the U.S. Food and Drug Administration (FDA) to develop a mechanistic framework for predicting in vivo performance of amorphous solid dispersion drug products, with the aim of supporting model informed drug development and potentially reducing reliance on some clinical bioequivalence studies (Key Developments).Seeking Alpha • Apr 12
Simulations Plus: Down Substantially, Not An Automatic Buy
Summary Simulations Plus trades at decade lows as investors question growth and AI disruption risks. SLP's Q2 sales grew 8% to $24.3M, but the full-year revenue outlook is flat to up 4%, with earnings guidance down. Valuation has compressed to 2.5x sales and ~20x realistic earnings, supported by a $42M net cash position. Despite improved margins and lower multiples, lack of growth and AI uncertainty keep me cautious on Simulations Plus. Read the full article on Seeking AlphaMise à jour du récit • Apr 12
SLP: AI Collaborations With Pharma And Regulators Will Drive Long-Term Upside
Analysts have reduced their price target for Simulations Plus from $20 to $16, citing updated assumptions that combine lower revenue growth expectations with a higher projected profit margin and a meaningfully lower future P/E multiple. What's in the News Simulations Plus announced collaboration programs with three large pharmaceutical companies to apply artificial intelligence within modeling workflows across the drug development lifecycle, using platforms such as GastroPlus, MonolixSuite, ADMET Predictor, and Thales (Key Developments).Article d’analyse • Feb 08
Simulations Plus, Inc.'s (NASDAQ:SLP) 26% Share Price Plunge Could Signal Some Risk
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders won't be pleased to see that the share price has had a very rough...Article d’analyse • Feb 06
Is There An Opportunity With Simulations Plus, Inc.'s (NASDAQ:SLP) 38% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$22.72 Simulations...
Mise à jour du récit • Jan 07
SLP: Reaffirmed Guidance And AI Roadmap Will Support Further Upside
Analysts have trimmed their price target on Simulations Plus to about US$22.33 per share, reflecting a slightly higher discount rate and P/E assumptions that point to a more cautious stance on profitability. What's in the News Simulations Plus plans an Analyst and Investor Day focused on presenting its new product vision and AI solutions, highlighting where management is aiming future product development (Key Developments).Mise à jour du récit • Dec 14
SLP: Reinforced Revenue Outlook Will Drive Upside From Current Levels
Analysts have modestly reduced their price target on Simulations Plus to approximately 22.33 dollars from 23 dollars. This reflects a recalibration of valuation multiples, even as they acknowledge stronger revenue growth and a significantly improved profit margin outlook.Mise à jour du récit • Nov 29
SLP: Revenue Guidance Will Support Renewed Upside Despite Index Exclusions
Analysts have maintained their price target for Simulations Plus at $23.00. They cited stable assumptions for revenue growth, profit margins, and valuation multiples in their latest assessment.Mise à jour du récit • Nov 15
SLP: Revenue Forecasts Will Drive Potential Gains Despite Index Removals
Analysts have modestly adjusted their price target for Simulations Plus from $23.00 to $23.00. They cite subtle changes in assumptions around discount rate and profit margins, while maintaining steady core growth expectations.Mise à jour du récit • Nov 01
SLP: Upcoming Earnings Guidance And Index Changes Will Drive Renewed Optimism
Analysts have adjusted their price target for Simulations Plus to $23.00. This reflects slight updates in their financial forecasts and expectations for future growth and profitability.Article d’analyse • Oct 28
Simulations Plus, Inc. (NASDAQ:SLP) Shares Could Be 44% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$32.42 Simulations...Mise à jour du récit • Oct 18
Software Licensing Expansion And Integrated Services Will Ensure Future Success
Analysts have maintained the fair value estimate for Simulations Plus at $23.00. This reflects stable long-term growth expectations, even with only slight adjustments to underlying assumptions.Mise à jour du récit • Oct 03
Software Licensing Expansion And Integrated Services Will Ensure Future Success
Analysts have revised their price target for Simulations Plus downward from $25.33 to $23.00, citing lower projected revenue growth and profit margins as key factors in their updated outlook. What's in the News Simulations Plus was removed from the S&P Composite 1500, S&P 1000, S&P 600, and S&P 600 Health Care indices (Key Developments).Article d’analyse • Jul 31
Some Simulations Plus, Inc. (NASDAQ:SLP) Shareholders Look For Exit As Shares Take 25% Pounding
Unfortunately for some shareholders, the Simulations Plus, Inc. ( NASDAQ:SLP ) share price has dived 25% in the last...Article d’analyse • Jun 13
Simulations Plus, Inc.'s (NASDAQ:SLP) Stock Retreats 36% But Earnings Haven't Escaped The Attention Of Investors
Simulations Plus, Inc. ( NASDAQ:SLP ) shares have had a horrible month, losing 36% after a relatively good period...Article d’analyse • May 07
Are Investors Undervaluing Simulations Plus, Inc. (NASDAQ:SLP) By 28%?
Key Insights The projected fair value for Simulations Plus is US$40.15 based on 2 Stage Free Cash Flow to Equity...Seeking Alpha • Apr 16
Simulations Plus: Benefiting From FDA Modernization And AI
Summary Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, including GastroPlus and ADMET Predictor, and consulting services position it as a comprehensive partner in biotech development. Favorable regulatory changes by the FDA towards AI and non-animal testing methods boost SLP's market potential, despite its current high valuation. SLP's long-term outlook remains strong due to its innovative approach and the growing adoption of AI in drug testing, making it a "Buy" for long-term investors. Read the full article on Seeking AlphaArticle d’analyse • Apr 13
Simulations Plus, Inc.'s (NASDAQ:SLP) 25% Jump Shows Its Popularity With Investors
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders would be excited to see that the share price has had a great month...Article d’analyse • Feb 08
Why Investors Shouldn't Be Surprised By Simulations Plus, Inc.'s (NASDAQ:SLP) 29% Share Price Surge
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders would be excited to see that the share price has had a great month...Article d’analyse • Jan 08
Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...Article d’analyse • Nov 07
We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be Conservative
Despite posting healthy earnings, Simulations Plus, Inc.'s ( NASDAQ:SLP ) stock has been quite weak. Along with the...
Nouveau récit • Oct 27
Biosimulation Innovations And Tactical Acquisitions To Boost Drug Development Growth
Integration and expansion into new markets drive revenue growth and improved profitability through increased efficiencies and enhanced offerings.Seeking Alpha • Aug 22
Simulations Plus: Declining Margins Are A Problem
Summary Simulations Plus growth is steady, but its margins continue to decline. This has been problematic due to the company's high valuation. Simulations Plus has suggested that the demand environment is improving, but its guidance implies a meaningful deceleration in organic growth. Simulations Plus likely needs to maintain its growth rate while improving margins before its share price moves higher. The decision to cut the company's dividend suggests that an improvement in margins and cash flows could be some way off. Read the full article on Seeking AlphaSeeking Alpha • Jul 10
Simulations Plus: Steady Growth, But What About The Margins?
Summary Simulations Plus, Inc. has seen stagnant stock trading despite impressive growth in the biosimulation market. Recent margin pressure and M&A activity raise concerns about management's ability to deliver. Acquisition of Pro-ficiency Holdings doubles the addressable market, but uncertainty remains about growth and margins amidst a demanding valuation. Read the full article on Seeking AlphaSeeking Alpha • May 14
Simulations Plus: Reliance On Consulting And Acquisitions Creates Doubts
Summary Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and underpenetrated, providing SLP with both organic and inorganic growth opportunities. While the company is operating in an attractive market and has a strong business, the company's valuation and growth prospects make the stock unappealing. Read the full article on Seeking AlphaAnalyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Feb 28 2026 | n/a | n/a | -US$63m |
| Nov 30 2025 | n/a | n/a | -US$64m |
| Aug 31 2025 | US$1m | US$525k | -US$65m |
| May 31 2025 | n/a | n/a | -US$63m |
| Feb 28 2025 | n/a | n/a | US$7m |
| Nov 30 2024 | n/a | n/a | US$8m |
| Aug 31 2024 | US$2m | US$512k | US$10m |
| May 31 2024 | n/a | n/a | US$10m |
| Feb 29 2024 | n/a | n/a | US$11m |
| Nov 30 2023 | n/a | n/a | US$11m |
| Aug 31 2023 | US$2m | US$487k | US$10m |
| May 31 2023 | n/a | n/a | US$10m |
| Feb 28 2023 | n/a | n/a | US$10m |
| Nov 30 2022 | n/a | n/a | US$11m |
| Aug 31 2022 | US$1m | US$450k | US$12m |
| May 31 2022 | n/a | n/a | US$12m |
| Feb 28 2022 | n/a | n/a | US$12m |
| Nov 30 2021 | n/a | n/a | US$10m |
| Aug 31 2021 | US$1m | US$444k | US$10m |
| May 31 2021 | n/a | n/a | US$12m |
| Feb 28 2021 | n/a | n/a | US$11m |
| Nov 30 2020 | n/a | n/a | US$10m |
| Aug 31 2020 | US$739k | US$350k | US$9m |
| May 31 2020 | n/a | n/a | US$9m |
| Feb 29 2020 | n/a | n/a | US$9m |
| Nov 30 2019 | n/a | n/a | US$9m |
| Aug 31 2019 | US$425k | US$325k | US$9m |
Rémunération vs marché: La rémunération totale de Shawn ($USD 1.10M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 1.74M ).
Rémunération et revenus: La rémunération de Shawn a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Shawn O'Connor (65 yo)
1.3yrs
Titularisation
US$1,096,572
Compensation
Mr. Shawn M. O'Connor serves as Chief Executive Officer of Simulations Plus, Inc. since 2025 and had been Chief Executive Officer since June 26, 2018 until 2025. Mr. O'Connor joined Simulations Plus, Inc....
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chief Executive Officer | 1.3yrs | US$1.10m | pas de données | |
| CFO, Executive VP & Corporate Secretary | 5.4yrs | US$534.65k | 0.010% $ 29.6k | |
| Chief Operating Officer | 1yr | US$358.27k | pas de données | |
| Chief Revenue Officer | 1yr | US$488.97k | 0.44% $ 1.2m | |
| President of Services Solutions | no data | US$465.08k | 0.39% $ 1.1m | |
| Global Head of Strategic Alliances | 1yr | US$482.28k | 0% $ 0 | |
| Accounting Manager | no data | pas de données | pas de données | |
| Chief Science Officer | 5.7yrs | pas de données | pas de données | |
| VP of Corporate Counsel & Personal Data Protection Officer | no data | pas de données | pas de données | |
| Senior Director of Corporate Marketing | no data | pas de données | pas de données | |
| Vice President of Human Resources | 4.3yrs | pas de données | pas de données | |
| Chief Science Officer of Quantitative Systems Pharmacology | 1.3yrs | pas de données | pas de données |
1.3yrs
Durée moyenne de l'emploi
55yo
Âge moyen
Gestion expérimentée: L'équipe de direction de SLP n'est pas considérée comme expérimentée (ancienneté moyenne 1.3 ans), ce qui suggère une nouvelle équipe.
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Director | 29.9yrs | US$155.27k | 16.17% $ 46.1m | |
| Independent Chairman of the Board | 9yrs | US$193.52k | 0.082% $ 233.3k | |
| Member of Scientific Advisory Board | 5.2yrs | pas de données | pas de données | |
| Chairman of Scientific Advisory Board | 5.2yrs | pas de données | pas de données | |
| Independent Director | 11.4yrs | US$180.02k | 0.072% $ 205.7k | |
| Member of Scientific Advisory Board | 5.2yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 5.2yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 5.2yrs | pas de données | pas de données | |
| Independent Director | 4.4yrs | US$175.52k | 0.085% $ 242.1k |
5.2yrs
Durée moyenne de l'emploi
67.5yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de SLP sont considérés comme expérimentés (ancienneté moyenne 5.2 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/20 17:31 |
| Cours de l'action en fin de journée | 2026/05/20 00:00 |
| Les revenus | 2026/02/28 |
| Revenus annuels | 2025/08/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Simulations Plus, Inc. est couverte par 11 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Larsen | BTIG |
| Dane Leone | CGS International |
| Constantine Davides | Citizens JMP Securities, LLC |